Date: 2012-02-16
Type of information: Private placement
Company: Protalix (Israel)
Investors:
Amount: $24.75 million (€18.8 million)
Funding type: private placement
Planned used: Protalix expects to use the net proceeds from the sale of the shares primarily to fund clinical trials for the Company\'s product candidates, to fund the Company\'s research and development activities, to enhance the Company\'s manufacturing capacity, for working capital and general corporate purposes.
Others: Protalix has announced the pricing of its underwritten public offering of 4.5 million shares of its common stock at a price to the public of $5.25 per share. The Company has granted the underwriters a 30-day option to purchase up to an aggregate of 675,000 additional shares of common stock to cover over-allotments, if any. The offering is expected to settle and close on February 22, 2012, subject to customary closing conditions.
* On February. 22, 2012, Protalix BioTherapeutics has announced the closing of its underwritten public offering. Prior to the closing, the underwriters exercised, in full, their over allotment option to purchase an additional 675,000 shares of common stock. As a result, Protalix sold a total of 5,175,000 shares of its common stock at a price to the public of $5.25 per share. After underwriting discounts and commissions and estimated offering expenses, the Company received net proceeds of approximately $25.4 million.
Therapeutic area: Rare diseases - Genetic diseases
